benzyl 3,3-difluoro-1-hydroxycyclopentanecarboxylate | 916736-73-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl 3,3-difluoro-1-hydroxycyclopentanecarboxylate
• 英文别名: (+)-Benzyl 3,3-difluoro-1-hydroxycyclopentanecarboxylate；benzyl 3,3-difluoro-1-hydroxycyclopentane-1-carboxylate
• CAS: 916736-73-7；916736-74-8；916736-75-9
• 化学式: C₁₃H₁₄F₂O₃
• 分子量: 256.249
• InChiKey: XIUTVXFGMXUTDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  benzyl 3,3-difluoro-1-hydroxycyclopentanecarboxylate 在 palladium 10% on activated carbon 氢气 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 2.0h， 生成 N-((1R)-1-{5-[5-chloro-3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-fluoropyridin-2-yl}ethyl)-3,3-difluoro-1-hydroxycyclopentanecarboxamide
  参考文献：
  名称：

  WO2006/132837

  摘要：

  公开号：
• 作为产物：
  描述：

  3-氧代-1-环戊烷羧酸 在 双(三甲基硅烷基)氨基钾 、 potassium carbonate 、 [双(2-甲氧基乙基)胺]三氟化硫 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 25.78h， 生成 benzyl 3,3-difluoro-1-hydroxycyclopentanecarboxylate
  参考文献：
  名称：

  WO2006/132837

  摘要：

  公开号：

文献信息

• 1-Hydroxycycloalkanecarboxamide derivatives
  申请人：Kuduk Scott D.

  公开号：US20090062349A1

  公开（公告）日：2009-03-05

  α-Hydroxycycloalkanecarboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, wherein formula (a) is a single or double bond; R 1 , R 2 and R 3 are each independently selected from H, halogen and OH; or R 1 and R 2 attached to the same carbon atom together represent oxo; R 4 is H or methyl; R 5 is Cl or I 2 ; R 6 is selected from —CO 2 —C 3-4 alkyl, —O—C 1-4 alkyl, —O—C 1-4 haloalkyl, 2-methyltetrazol-5-yl, 5-methyl-1,2,4-oxadiazol-3-yl, 3-methyl-1,2,4-oxadiazol-5-yl, 5-halomethyl-1,2,4-oxadiazol-3-yl, 3-halomethyl-1,2,4-oxadiazol-5-yl, tetrazol-5-yl, 5-halomethyl-1,2,3-triazolyl, and 5-methyl-1,2,3-triazolyl; R 7 and R 8 are each independently Cl or I 2 ; and n is 0 or 1, are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

  式(I)中，α-羟基环烷基羧酰胺衍生物或其药学上可接受的盐，其中式(a)为单键或双键；R1、R2和R3各自独立地选自H、卤素和OH；或者R1和R2结合到同一碳原子上表示氧代基；R4为H或甲基；R5选自Cl或I2；R6选自—CO2—C3-4烷基、—O—C1-4烷基、—O—C1-4卤代烷基、2-甲基四唑-5-基、5-甲基-1,2,4-噁二唑-3-基、3-甲基-1,2,4-噁二唑-5-基、5-卤代甲基-1,2,4-噁二唑-3-基、3-卤代甲基-1,2,4-噁二唑-5-基、四唑-5-基、5-卤代甲基-1,2,3-三唑基和5-甲基-1,2,3-三唑基；R7和R8各自独立地选自Cl或I2；n为0或1。这些化合物是Bradykinin B1拮抗剂或反向激动剂，可用于治疗或预防与Bradykinin B1通路相关的疼痛和炎症症状。
• 1-hydroxycycloalkanecarboxamide derivatives
  申请人：Merck Sharp & Dohme Corp.

  公开号：US07816380B2

  公开（公告）日：2010-10-19

  α-Hydroxycycloalkanecarboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, wherein formula (a) is a single or double bond; R1, R2 and R3 are each independently selected from H, halogen and OH; or R1 and R2 attached to the same carbon atom together represent oxo; R4 is H or methyl; R5 is Cl or I2; R6 is selected from —CO2—C1-4alkyl, —O—C1-4alkyl, —O—C1-4haloalkyl, 2-methyltetrazol-5-yl, 5-methyl-1,2,4-oxadiazol-3-yl, 3-methyl-1,2,4-oxadiazol-5-yl, 5-halomethyl-1,2,4-oxadiazol-3-yl, 3-halomethyl-1,2,4-oxadiazol-5-yl, tetrazol-5-yl, 5-halomethyl-1,2,3-triazolyl, and 5-methyl-1,2,3-triazolyl; R7 and R8 are each independently Cl or I2; and n is 0 or 1, are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

  式(I)或其药学上可接受的盐，其中式(a)表示单键或双键；R1、R2和R3各自独立地选择自H、卤素和OH；或者R1和R2结合到同一碳原子上表示氧代；R4为H或甲基；R5为Cl或I2；R6选择自—CO2—C1-4烷基、—O—C1-4烷基、—O—C1-4卤代烷基、2-甲基四唑-5-基、5-甲基-1,2,4-噁二唑-3-基、3-甲基-1,2,4-噁二唑-5-基、5-卤代甲基-1,2,4-噁二唑-3-基、3-卤代甲基-1,2,4-噁二唑-5-基、四唑-5-基、5-卤代甲基-1,2,3-三唑基和5-甲基-1,2,3-三唑基；R7和R8各自独立地为Cl或I2；n为0或1。这些化合物是Bradykinin B1拮抗剂或反向激动剂，用于治疗或预防与Bradykinin B1通路相关的疼痛和炎症等症状。
• Bradykinin B1 receptor antagonists: An α-hydroxy amide with an improved metabolism profile
  作者：Scott D. Kuduk、Ronald K. Chang、Robert M. DiPardo、Christina N. Di Marco、Kathy L. Murphy、Richard W. Ransom、Duane R. Reiss、Cuyue Tang、Thomayant Prueksaritanont、Douglas J. Pettibone、Mark G. Bock

  DOI：10.1016/j.bmcl.2008.07.126

  日期：2008.9

  A series of carbo-and heterocyclic alpha-hydroxy amide-derived bradykinin B(1) antagonists were prepared and evaluated. A 4,4-difluorocyclohexyl alpha-hydroxy amide was incorporated along with a 2-methyl tetrazole in lieu of an oxadiazole to afford a suitable compound with good pharmacokinetic properties, CNS penetration, and clearance by multiple metabolic pathways. (C) 2008 Elsevier Ltd. All rights reserved.
• 1-HYDROXYCYCLOALKANECARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP1893579B1

  公开（公告）日：2013-05-01
• US7816380B2
  申请人：——

  公开号：US7816380B2

  公开（公告）日：2010-10-19